摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

((3S,4R)-4-(-4-fluorophenyl)-1-methylpiperidin-3-yl)methanol-d2 | 946119-86-4

中文名称
——
中文别名
——
英文名称
((3S,4R)-4-(-4-fluorophenyl)-1-methylpiperidin-3-yl)methanol-d2
英文别名
dideuterio-[(3S,4R)-4-(4-fluorophenyl)-1-methylpiperidin-3-yl]methanol
((3S,4R)-4-(-4-fluorophenyl)-1-methylpiperidin-3-yl)methanol-d2化学式
CAS
946119-86-4
化学式
C13H18FNO
mdl
——
分子量
225.275
InChiKey
CXRHUYYZISIIMT-YSDLUYJASA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.8
  • 重原子数:
    16
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.54
  • 拓扑面积:
    23.5
  • 氢给体数:
    1
  • 氢受体数:
    3

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • NOVEL BENZO[D][1,3]-DIOXOL DERIVATIVES
    申请人:Tung Roger
    公开号:US20080033011A1
    公开(公告)日:2008-02-07
    The present invention relates to an isotopologue of paroxetine substituted with deuterium at the methylene carbon of the benzodioxol ring. The isotopologues of this invention selective serotonin reuptake inhibitors (SSRIs) and possess unique biopharmaceutical and metabolic properties compared to paroxetine. They may also be used to accurately determine the concentration of paroxetine in biological fluids and to determine metabolic patterns of paroxetine and its isotopologues. The invention further provides compositions comprising these deuterated isotopologues and methods of treating diseases and conditions that are responsive to increased neuronal serotonin transmission, alone and in combination with additional agents.
    本发明涉及一种取代苯并二氧戊环环上亚甲基碳上的氘代帕罗西汀同位素。本发明的同位素是选择性血清素再摄取抑制剂(SSRIs),与帕罗西汀相比具有独特的生物制药和代谢特性。它们还可以用于准确测定生物液体中帕罗西汀的浓度以及确定帕罗西汀及其同位素的代谢模式。本发明还提供了包含这些氘代同位素的组合物和治疗对增加神经元血清素传递敏感的疾病和状况的方法,单独或与其他药物联合使用。
  • Novel benzo[D][1,3]-dioxol derivatives
    申请人:Tung Roger
    公开号:US20070191432A1
    公开(公告)日:2007-08-16
    The present invention relates to an isotopologue of Compound 1 substituted with deuterium at the methylene carbon of the benzodioxol ring. The isotopologues of this invention selective serotonin reuptake inhibitors (SSRIs) and possess unique biopharmaceutical and metabolic properties compared to Compound 1. They may also be used to accurately determine the concentration of Compound 1 in biological fluids and to determine metabolic patterns of Compound 1 and its isotopologues. The invention further provides compositions comprising these deuterated isotopologues and methods of treating diseases and conditions that are responsive to increased neuronal serotonin transmission, alone and in combination with additional agents.
    本发明涉及一种在苯并二氧杂环环的亚甲基碳上取代氘的化合物1的同位素。本发明的同位素是选择性血清素再摄取抑制剂(SSRI),与化合物1相比具有独特的生物制药和代谢特性。它们还可以用于准确确定生物液中化合物1的浓度,并确定化合物1及其同位素的代谢模式。本发明还提供了包含这些氘同位素的组合物以及治疗对增加神经元血清素传递敏感的疾病和病症的方法,单独或与其他药物联合使用。
  • DEUTERATED BENZO[D][1,3]-DIOXOL DERIVATIVES
    申请人:Tung Roger D.
    公开号:US20140018390A1
    公开(公告)日:2014-01-16
    The present invention relates to an isotopologue of Compound 1 substituted with deuterium at the methylene carbon of the benzodioxol ring. The isotopologues of this invention selective serotonin reuptake inhibitors (SSRIs) and possess unique biopharmaceutical and metabolic properties compared to Compound 1. They may also be used to accurately determine the concentration of Compound 1 in biological fluids and to determine metabolic patterns of Compound 1 and its isotopologues. The invention further provides compositions comprising these deuterated isotopologues and methods of treating diseases and conditions that are responsive to increased neuronal serotonin transmission, alone and in combination with additional agents.
    本发明涉及一种在苯并二氧杂环环的亚甲基碳上以氘代替的化合物1的同位素。本发明的同位素是选择性血清素再摄取抑制剂(SSRI),与化合物1相比具有独特的生物制药和代谢特性。它们还可以用于准确测定生物液体中化合物1的浓度,并确定化合物1及其同位素的代谢模式。本发明还提供了包含这些氘代同位素的组合物和治疗对增加神经元血清素传递敏感的疾病和病症的方法,以及与其他药物联合使用的方法。
  • NOVEL BENZO[d][1,3]-DIOXOL DERIVATIVES
    申请人:Tung Roger D.
    公开号:US20150196544A1
    公开(公告)日:2015-07-16
    The present invention relates to an isotopologue of Compound 1 substituted with deuterium at the methylene carbon of the benzodioxol ring. The isotopologues of this invention selective serotonin reuptake inhibitors (SSRIs) and possess unique biopharmaceutical and metabolic properties compared to Compound 1. They may also be used to accurately determine the concentration of Compound 1 in biological fluids and to determine metabolic patterns of Compound 1 and its isotopologues. The invention further provides compositions comprising these deuterated isotopologues and methods of treating diseases and conditions that are responsive to increased neuronal serotonin transmission, alone and in combination with additional agents.
    本发明涉及化合物1的同位素拓扑异构体,在苯并二氧杂环环的亚甲基碳上用氘取代。本发明的同位素拓扑异构体是选择性血清素再摄取抑制剂(SSRI),与化合物1相比具有独特的生物制药和代谢特性。它们还可以用于准确测定生物流体中化合物1的浓度,并确定化合物1及其同位素拓扑异构体的代谢模式。本发明还提供了包含这些氘化同位素拓扑异构体的组合物及其治疗对增加神经元血清素传递响应的疾病和病状的方法,单独使用或与其他药物联合使用。
  • Synthesis of deuterated catechols and benzo[D][1,3]dioxoles and derivatives thereof
    申请人:Jones Andrew D.
    公开号:US20090143432A1
    公开(公告)日:2009-06-04
    The present invention provides a convenient and efficient process for the synthesis of d 2 -benzo[d][1,3]dioxoles.
查看更多